Limpet_Chicken
Bluelighter
- Joined
- Oct 13, 2005
- Messages
- 6,323
Of late, I have been reading a little about a class of structurally novel opioidergics, represented by a 1-acyl-4-cinnamylpiperazine backbone, the most potent of the class without any further modifications appears to be 1-butyryl-4-cinnamylpiperazine.
Reading up on it, it seems in this study, comparing the drug with aminopyrin, that the 1-propionamide at least, behaved like an opioid agonist rather than an antiinflammatory such as an NSAID or crAPAP, but there appear to be very widely conflicting results about tolerance.
This drug, AP-237 is the 1-(n)-butyryl amide and it seems has a fairly long history of use in china. Unfortunately I ended up running into what looked like it was probably some paywall filth, although I couldn't be sure since I do not speak or read chinese.
There are quite a few journal references which try to suggest that it has relatively little propensity towards developing physical tolerance and habituation, yet the wikipedia states that it does so quickly.
More to folllow on here.
Reading up on it, it seems in this study, comparing the drug with aminopyrin, that the 1-propionamide at least, behaved like an opioid agonist rather than an antiinflammatory such as an NSAID or crAPAP, but there appear to be very widely conflicting results about tolerance.
This drug, AP-237 is the 1-(n)-butyryl amide and it seems has a fairly long history of use in china. Unfortunately I ended up running into what looked like it was probably some paywall filth, although I couldn't be sure since I do not speak or read chinese.
There are quite a few journal references which try to suggest that it has relatively little propensity towards developing physical tolerance and habituation, yet the wikipedia states that it does so quickly.
More to folllow on here.